YU10101A - Prolekovi inhibitori proton pumpe - Google Patents
Prolekovi inhibitori proton pumpeInfo
- Publication number
- YU10101A YU10101A YU10101A YU10101A YU10101A YU 10101 A YU10101 A YU 10101A YU 10101 A YU10101 A YU 10101A YU 10101 A YU10101 A YU 10101A YU 10101 A YU10101 A YU 10101A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- proton pump
- prodrugs
- drugs
- pump inhibitor
- under physiological
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Reciprocating Pumps (AREA)
- Fertilizing (AREA)
Abstract
Prolekovi piridil, metil, sulfinil, benzimidazol, tipa lekova inhibitora proton pumpe imaju hidrolizabilnu sulfinil ili arilsulfonil grupu pričvršćenu na azot benzimidazola, ili sadrže grupu koja formira Mannich baze sa benzimidazol azotom. Prolekovi pronalaska hidrolizuju u fiziološkim uslovima da bi obezbedili inhibitore proton pumpe sa poluživotom koji se može meriti u časovima, i sposobni su da obezbede ustaljene plazma koncentracije lekova inhibitora proton pumpe duže vremena nego lekovi koji su danas u upotrebi. Generisanje lekova inhibitora proton pumpe iz prolekova pronalaska u fiziološkim uslovima omogućuje efektivniji tretman nekoliko bolesti i stanja izazvanih sekrecijom želudačne kiseline.[Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a i(Mannich) base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/131,481 US6093734A (en) | 1998-08-10 | 1998-08-10 | Prodrugs of proton pump inhibitors |
| US36438199A | 1999-07-29 | 1999-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU10101A true YU10101A (sh) | 2003-10-31 |
Family
ID=26829517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU10101A YU10101A (sh) | 1998-08-10 | 1999-08-09 | Prolekovi inhibitori proton pumpe |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6559167B1 (sh) |
| EP (1) | EP1105387B1 (sh) |
| JP (1) | JP4346243B2 (sh) |
| KR (1) | KR100472126B1 (sh) |
| CN (1) | CN100396675C (sh) |
| AT (1) | ATE231857T1 (sh) |
| AU (1) | AU752292B2 (sh) |
| BG (1) | BG64870B1 (sh) |
| BR (1) | BR9912937A (sh) |
| CA (1) | CA2338311C (sh) |
| DE (1) | DE69905171T2 (sh) |
| DK (1) | DK1105387T3 (sh) |
| ES (1) | ES2192394T3 (sh) |
| FI (1) | FI20010248A7 (sh) |
| HR (1) | HRP20010106A2 (sh) |
| HU (1) | HUP0103464A3 (sh) |
| ID (1) | ID28273A (sh) |
| IL (2) | IL141083A0 (sh) |
| IS (1) | IS5826A (sh) |
| MX (1) | MXPA01001464A (sh) |
| NO (1) | NO322490B1 (sh) |
| NZ (1) | NZ510180A (sh) |
| PL (1) | PL346000A1 (sh) |
| TR (1) | TR200100431T2 (sh) |
| UA (1) | UA67788C2 (sh) |
| WO (1) | WO2000009498A1 (sh) |
| YU (1) | YU10101A (sh) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2467652A1 (en) * | 2001-11-19 | 2003-05-30 | Altana Pharma Ag | Reversible proton pump inhibitors for the treatment of airway disorders |
| DE60304726T2 (de) * | 2002-07-19 | 2007-08-09 | Winston Pharmaceuticals Llc, Newport Beach | Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer |
| JP2006188432A (ja) * | 2003-02-25 | 2006-07-20 | Zeria Pharmaceut Co Ltd | 四環系スルフェンアミド化合物 |
| AU2004264401A1 (en) * | 2003-07-15 | 2005-02-24 | Allergan, Inc. | Process for preparing isomerically pure prodrugs of proton pump inhibitors |
| KR20060118421A (ko) * | 2003-08-29 | 2006-11-23 | 다이노젠 파마세우티컬스, 인코포레이티드 | 위장 운동 장애의 치료에 유용한 조성물 |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| WO2005039640A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
| AU2005216863A1 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors |
| JP2007523163A (ja) * | 2004-02-18 | 2007-08-16 | アラーガン、インコーポレイテッド | プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物 |
| EP1742630A4 (en) * | 2004-04-16 | 2010-01-20 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND PROKINETIC AGENT |
| EP1740571B1 (en) * | 2004-04-28 | 2009-07-29 | Hetero Drugs Limited | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
| DE602004025386D1 (de) * | 2004-05-28 | 2010-03-18 | Hetero Drugs Ltd | Neue stereoselektive synthese von benzimidazolsulfoxiden |
| KR20070027584A (ko) * | 2004-06-17 | 2007-03-09 | 와이어쓰 | 고나도트로핀 방출 호르몬 수용체 길항제 |
| AU2005264998A1 (en) * | 2004-06-17 | 2006-01-26 | Wyeth | The present invention relates to methods of making Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists |
| CA2581454A1 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| CA2587853A1 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) * | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
| US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| CA2611917A1 (en) * | 2005-06-13 | 2006-12-21 | Takeda Pharmaceutical Company Limited | Injection |
| WO2007073301A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Benzoimidazole derivatives as prodrugs of proton pump inhibitors |
| WO2008036201A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
| WO2008036211A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| CA2667682A1 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
| CN101497622B (zh) * | 2008-01-30 | 2011-04-27 | 山东轩竹医药科技有限公司 | 吡啶甲基亚磺酰基咪唑并吡啶衍生物 |
| JP2011512416A (ja) | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
| UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| CA2891523A1 (en) * | 2012-11-19 | 2014-05-22 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pyrrole sulfonamide derivative, preparation method for same, and medical application thereof |
| WO2014133059A1 (ja) | 2013-02-28 | 2014-09-04 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| JP7799627B2 (ja) | 2020-05-20 | 2026-01-15 | エフ． ホフマン－ラ ロシュ アーゲー | 質量分析のための試薬 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| SE8505112D0 (sv) * | 1985-10-29 | 1985-10-29 | Haessle Ab | Novel pharmacological compounds |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| WO1991019712A1 (en) * | 1990-06-20 | 1991-12-26 | Aktiebolaget Astra | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| SE9602442D0 (sv) | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
-
1999
- 1999-08-09 TR TR2001/00431T patent/TR200100431T2/xx unknown
- 1999-08-09 WO PCT/US1999/018048 patent/WO2000009498A1/en not_active Ceased
- 1999-08-09 CA CA002338311A patent/CA2338311C/en not_active Expired - Lifetime
- 1999-08-09 AT AT99942057T patent/ATE231857T1/de not_active IP Right Cessation
- 1999-08-09 AU AU55518/99A patent/AU752292B2/en not_active Expired
- 1999-08-09 YU YU10101A patent/YU10101A/sh unknown
- 1999-08-09 NZ NZ510180A patent/NZ510180A/xx not_active IP Right Cessation
- 1999-08-09 ID IDW20010545A patent/ID28273A/id unknown
- 1999-08-09 KR KR10-2001-7001705A patent/KR100472126B1/ko not_active Expired - Fee Related
- 1999-08-09 ES ES99942057T patent/ES2192394T3/es not_active Expired - Lifetime
- 1999-08-09 IL IL14108399A patent/IL141083A0/xx active IP Right Grant
- 1999-08-09 HR HR20010106A patent/HRP20010106A2/hr not_active Application Discontinuation
- 1999-08-09 HU HU0103464A patent/HUP0103464A3/hu unknown
- 1999-08-09 CN CNB998095125A patent/CN100396675C/zh not_active Expired - Fee Related
- 1999-08-09 PL PL99346000A patent/PL346000A1/xx not_active IP Right Cessation
- 1999-08-09 JP JP2000564950A patent/JP4346243B2/ja not_active Expired - Fee Related
- 1999-08-09 EP EP99942057A patent/EP1105387B1/en not_active Expired - Lifetime
- 1999-08-09 MX MXPA01001464A patent/MXPA01001464A/es not_active IP Right Cessation
- 1999-08-09 DK DK99942057T patent/DK1105387T3/da active
- 1999-08-09 BR BR9912937-0A patent/BR9912937A/pt not_active Application Discontinuation
- 1999-08-09 DE DE69905171T patent/DE69905171T2/de not_active Expired - Lifetime
- 1999-09-08 UA UA2001020908A patent/UA67788C2/uk unknown
-
2001
- 2001-01-24 IL IL141083A patent/IL141083A/en not_active IP Right Cessation
- 2001-01-26 IS IS5826A patent/IS5826A/is unknown
- 2001-01-26 BG BG105191A patent/BG64870B1/bg unknown
- 2001-02-09 NO NO20010693A patent/NO322490B1/no not_active IP Right Cessation
- 2001-02-09 FI FI20010248A patent/FI20010248A7/fi unknown
- 2001-02-14 US US09/783,807 patent/US6559167B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU10101A (sh) | Prolekovi inhibitori proton pumpe | |
| ATE325128T1 (de) | Substituierte aminoalkanphosphonsäuren | |
| TR200103493T2 (tr) | Metaloproteaz önleyicileri | |
| CY1109391T1 (el) | Παραγωγα του υδροξαμικου οξεος, αναστολεις του ενζυμου ιστονοδεακετυλαση, που χρησιμοποιουνται ως νεα αντιφλεγμονωδη φαρμακα αναστολεις της συνθεσης της κιτοκινης | |
| TR200201144T2 (tr) | NFKB aktivitesinin modülasyonu için ikame edilmiş indoller | |
| CY1111061T1 (el) | Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων | |
| ATE301651T1 (de) | Substituierte benzimidazole | |
| IL166371A0 (en) | Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor | |
| AR017172A1 (es) | Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden | |
| EA200101230A1 (ru) | Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции | |
| DE69727583D1 (de) | Vermeidung von gastrointestinaler schädigung | |
| TR200100084T2 (tr) | İlaç olarak fosfin-ve fosfon asit türevleri | |
| DK1246790T3 (da) | Substituerede 1- og 2-naphthol-Mannichbaser | |
| BG108144A (en) | New use | |
| TR200201141T2 (tr) | 2-Amino-3,4-dihidro-kinazolinlerin bir ilacın üretiminde kullanımı | |
| NO20052313L (no) | Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av | |
| ITMI931418A1 (it) | Enantiomeri farmacologicamente attivi | |
| DK1220844T3 (da) | Arylsulfonamid-substituerede benzimidazolderivater og deres anvendelse som tryptase-inhibitorer | |
| DK2014290T3 (da) | Anvendelse af tenatoprazol til behandling af gastroøsofageal refluks | |
| NO20061354L (no) | Fremgangsmater og sammensetninger for oral administrering av prodroger av protonpumpe inhibitatorer | |
| TR200000244T2 (tr) | MCP-1 proteini üretimini azaltmada etkin bir farmasötik bileşim. | |
| ATE247092T1 (de) | Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren | |
| TH41955A (th) | การใช้ควินอกซาบีนส์ในสารรวม 3 ชนิดกับตัวหยุดยั้งทรานส์คริปเตสผันกลับเป็นยารักษาโรคเอดส์หรือการติดเชื้อ hiv |